-
Mashup Score: 14Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations - 3 month(s) ago
BAY 2927088 is an oral, small molecule tyrosine kinase inhibitor under development as a potential new targeted therapy for patients with NSCLC harboring HER2 activating mutations / Breakthrough Therapy designation is a process designed to expedite the development and review of investigational drugs that have potential to provide substantial impr…
Source: www.bayer.comCategories: General Medicine News, Hem/OncsTweet
🔥@FDAOncology Breakthrough Therapy designation for the BAY-2927088 (oral non-covalent selective TKI) for #lungcancer harboring #HER2 activating mutations #LCSM https://t.co/ObtBB3IF5A